Herantis Pharma (Herantis Pharma) Cash-to-Debt : 186.18 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Herantis Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Herantis Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 186.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Herantis Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Herantis Pharma's Cash-to-Debt or its related term are showing as below:

HRPMF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34 Med: 1.14 Max: 185.37
Current: 185.37

During the past 13 years, Herantis Pharma's highest Cash to Debt Ratio was 185.37. The lowest was 0.34. And the median was 1.14.

HRPMF's Cash-to-Debt is ranked better than
82.34% of 1523 companies
in the Biotechnology industry
Industry Median: 6.39 vs HRPMF: 185.37

Herantis Pharma Cash-to-Debt Historical Data

The historical data trend for Herantis Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Herantis Pharma Cash-to-Debt Chart

Herantis Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.97

1.85

1.41

1.32

186.18

Herantis Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1.41	1.45	1.32	1.08	186.18

Competitive Comparison of Herantis Pharma's Cash-to-Debt

For the Biotechnology subindustry, Herantis Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Herantis Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Herantis Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Herantis Pharma's Cash-to-Debt falls into.

Herantis Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Herantis Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.075	/	(0.005	+	0.033)
	=	186.18

Herantis Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.075	/	(0.005	+	0.033)
	=	186.18

Herantis Pharma (OTCPK:HRPMF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Herantis Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Herantis Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Herantis Pharma (Herantis Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Herantis Pharma PLC (OTCPK:HRPMF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HRTIS:Finland

Address

Bertel Jungin Aukio 1, Espoo, FIN, 02600

Website

https://www.herantis.com

Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.

Herantis Pharma (Herantis Pharma) Headlines

From GuruFocus

Herantis Pharma Plc Completes Patient Recruitment and Treatment in Phase 2 AdeLE Trial in Breast Cancer Associated Lymphedema

By PRNewswire PRNewswire • 12-17-2019

Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

By PRNewswire PRNewswire • 02-25-2020